The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
ResMed (RMD) reported steady revenue growth but a decline in operating margin for its Q2 earnings, largely due to higher R&D and supply chain costs, and a $42 million charge for a field safety action. Analysts focused on gross margin drivers, revenue growth acceleration, …